JP Morgan Chase’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-5,069
Closed -$13K 6022
2020
Q2
$13K Buy
+5,069
New +$9.61K ﹤0.01% 5102
2019
Q4
Sell
-6,068
Closed -$32K 6035
2019
Q3
$32K Buy
6,068
+247
+4% +$1.65K ﹤0.01% 5310
2019
Q2
$56K Buy
5,821
+5,177
+804% +$95.3K ﹤0.01% 5129
2019
Q1
$17K Sell
644
-30,760
-98% -$783K ﹤0.01% 5442
2018
Q4
$709K Buy
31,404
+1,160
+4% +$45.4K ﹤0.01% 3946
2018
Q3
$1.67M Sell
30,244
-831
-3% -$53.1K ﹤0.01% 3579
2018
Q2
$2.22M Buy
31,075
+24,289
+358% +$1.71M ﹤0.01% 3342
2018
Q1
$417K Sell
6,786
-51,633
-88% -$4.53M ﹤0.01% 4081
2017
Q4
$7.36M Sell
58,419
-1,546
-3% -$198K ﹤0.01% 2363
2017
Q3
$7.92M Buy
+59,965
New +$8.02M ﹤0.01% 2182
2017
Q2
Sell
-1,156
Closed -$212K 5358
2017
Q1
$212K Buy
1,156
+542
+88% +$60.8K ﹤0.01% 4050
2016
Q4
$49K Buy
614
+561
+1,058% +$44.4K ﹤0.01% 4556
2016
Q3
$4K Sell
53
-51
-49% -$4.09K ﹤0.01% 4393
2016
Q2
$9K Buy
104
+95
+1,056% +$8.7K ﹤0.01% 4363
2016
Q1
$1K Sell
9
-1
-10% -$100 ﹤0.01% 4600
2015
Q4
$3K Buy
+10
New +$2K ﹤0.01% 4475
2014
Q2
Sell
-1,470
Closed -$320K 3665
2014
Q1
$320K Buy
+1,470
New +$410K ﹤0.01% 3269

JP Morgan Chase's TTPH Position: Q3 2020 in Review

JP Morgan Chase sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 5,069 shares — an estimated $13K sold.

JP Morgan Chase first reported a position in TTPH in Q1 2014 and held it in 17 quarters. The position peaked at $7.92M in Q3 2017. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.

  • JP Morgan Chase reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • JP Morgan Chase sold 5,069 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $13K.
  • JP Morgan Chase first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 17 quarters.
  • JP Morgan Chase's Tetraphase Pharmaceuticals, Inc. position peaked at $7.92M in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.

Based on JP Morgan Chase's 13F filing for Q3 2020, filed 12 Nov 2020.